---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-26-004991"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2026-08-13T20:32:38+00:00"
generated_at: "2026-08-13T20:34:23.764351+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# VolitionRx Q2 2026: H1 revenue up 112% to $1.4M, operating loss down 34%

## Summary
- H1 2026 revenue $1.4M, up 112% YoY; Q2 revenue ~$0.4M, flat YoY.
- Q2 operating loss $4.2M, down 34% YoY; operating expenses down 32%.
- Net cash used in ops $5.2M in Q2, down 18% YoY; raised $5.3M from equity sales.
- In talks with 12+ diagnostic/liquid biopsy firms for licensing; Sysmex collaboration announced.
- Nu.Q Vet feline assay manuscript submitted; publication could unlock $5M milestone.

## SEC filing metadata
- accession: 0001477932-26-004991
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2026-08-13T20:32:38+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793226004991/0001477932-26-004991-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793226004991/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-26-004991
- JSON: https://secwatch.observer/filing/0001477932-26-004991.json
- Plain text: https://secwatch.observer/filing/0001477932-26-004991.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.